Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company whose news flow reflects its role in life science tools, bioactive reagents, diagnostics, and spatial biology. Company announcements frequently highlight financial results, product launches, collaborations, and participation in healthcare and investor conferences, giving investors and researchers insight into how Bio-Techne is executing its strategy.
Recent press releases include quarterly and annual financial updates, where Bio-Techne reports net sales, segment performance for its Protein Sciences and Diagnostics and Spatial Biology segments, and commentary on market conditions. These earnings communications often discuss organic revenue trends, operating margins, and portfolio decisions such as divestitures of non-core businesses.
Product and technology news from Bio-Techne covers launches of analytical instruments, spatial biology assays, and multiomic workflows. Examples include announcements of next-generation protein analysis systems with multiplexing capabilities, spatial biology platforms that combine RNA and protein detection, and assays that visualize protein-protein interactions within tissue at subcellular resolution. Such updates show how the company is expanding its proteomic analytical tools and spatial biology offerings, which it identifies as growth pillars.
Bio-Techne also issues news about strategic collaborations and licensing agreements. Recent items describe partnerships in AI-enabled protein design, multiomic spatial analysis with academic and industry partners, and initiatives supporting cell and gene therapy manufacturing workflows. In addition, the company regularly announces its participation in major healthcare and investor conferences, where management presents its outlook and strategy.
This TECH news page aggregates these types of updates so readers can follow Bio-Techne’s financial reporting, product innovation, strategic partnerships, and conference activity in one place. Investors, analysts, and scientists can use this feed to monitor developments across the company’s life science tools, diagnostics, and spatial biology businesses.
Bio-Techne (NASDAQ: TECH) has achieved IVDR certification for its R&D Systems Hematology Controls and Calibrators, confirming compliance with European Union regulations for in-vitro diagnostic devices. This certification underscores the products' high quality, accuracy, precision, and reliability. It represents a significant milestone in Bio-Techne's dedication to supporting healthcare professionals with top-tier laboratory components. The certified Hematology Controls and Calibrators are vital for ensuring accurate patient testing in laboratories, meeting stringent hematology standards.
Bio-Techne (NASDAQ: TECH) has announced its participation in three upcoming investor conferences in November 2024. The company will present at the UBS Global Healthcare Conference on November 12 at 9:30 AM PST, the Stifel 2024 Healthcare Conference on November 19 at 8:00 AM EST, and the Stephens NASH 2024 Conference on November 20 at 11:00 AM CST. Interested parties can access live webcasts of all presentations through Bio-Techne's Investor Relations website's IR Calendar page.
ScaleReady has awarded G-Rex Grants totaling $475,000 to three leading investigators at Baylor College of Medicine's Center for Cell and Gene Therapy (CAGT).
Dr. Ann Leen received $275,000 for research on T cell therapies for AML and MDS. Dr. Katie McKenna received $100,000 to develop 3D tumor spheroid models. Dr. Dimitrios Laurin Wagner and Dr. Marie Pouzolles received $100,000 for non-viral gene editing platforms to create immune cell therapies.
The G-Rex Grant Program is a $20M initiative aimed at advancing cell and gene therapy development and manufacturing.
Bio-Techne (NASDAQ: TECH) will showcase its portfolio at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting from November 6-10, 2024, in Houston, Texas. The company's spatial biology brands, Advanced Cell Diagnostics (ACD) and Lunaphore, will present their innovations at booths #613 and #701 respectively.
ACD will showcase spatial multiomics products featuring RNAscope™ technology, while Lunaphore will demonstrate its automated COMET™ suite and HORIZON™ image analysis software. The company will present multiple posters highlighting research applications, including multiomic mapping of the brain, immune cell profiling, and biomarker detection studies. Collaborative research presentations with prominent institutions will also be featured.
Bio-Techne announced significant clinical data from its Lunaphore COMET spatial biology platform. The platform integrates with clinical research workflows and uses IHC-validated antibodies for rapid panel development. Research conducted with the National Tumor Institute and Nucleai revealed tumor microenvironment features that could predict therapy response in melanoma patients. The study combined multiplex immunofluorescence with AI-powered biomarker analysis, marking the first application of this technology in a clinical trial. Additional research with Johns Hopkins University demonstrated the platform's novel amplification technique for comprehensive tumor profiling.
Bio-Techne (NASDAQ: TECH) has declared a quarterly dividend of $0.08 per share for the quarter ended September 30, 2024. The dividend will be paid on November 22, 2024, to shareholders of record as of November 11, 2024. The company, which provides innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of approximately $1.2 billion in fiscal 2024 and employs around 3,100 people globally.
Bio-Techne (NASDAQ: TECH) reported Q1 FY2025 results with organic revenue growth of 4% (5% reported) to $289.5 million. GAAP EPS decreased to $0.21 from $0.31 year-over-year, while adjusted EPS slightly increased to $0.42 from $0.41. The Diagnostics & Spatial Biology segment showed strong performance with 14% organic growth. The Protein Sciences segment remained flat at $204.5 million with 1% organic growth. GAAP operating margin declined to 13.8% from 20.2%, while adjusted operating margin decreased to 29.0% from 31.4% due to product mix and compensation accruals.
ScaleReady announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant in collaboration with Wilson Wolf Manufacturing and Bio-Techne (NASDAQ: TECH). The grant will support development of novel CAR γδ T cell therapies for autoimmune conditions. Luminary's approach combines Vδ1 and Vδ2 subsets with immune cloaking mechanism and utilizes Bio-Techne's TcBuster™ technology. The company claims their manufacturing process can produce 180-200 patient doses per run at less than $10,000 per drug product. The grant is part of ScaleReady's $20M initiative to advance cell and gene therapy development.
Bio-Techne (NASDAQ: TECH) has announced a conference call and webcast scheduled for October 30, 2024, at 8:00 a.m. CDT to discuss its first quarter fiscal 2025 financial results. Interested parties can access the call via phone or webcast. The dial-in numbers are 1-877-407-9208 for domestic callers and 1-201-493-6784 for international callers, with the Conference ID 13749405. A webcast link is also provided.
For those unable to join the live call, a recorded rebroadcast will be available from 11:00 a.m. CDT on October 30, 2024, until 11:00 p.m. CST on November 30, 2024. The replay can be accessed by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and using the same Conference ID.
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $300,000 G-Rex® Grant to LIfT BioSciences. This grant will support the clinical manufacturing of LIfT's Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform, a promising allogeneic innate cell therapy.
The N-LIfT platform produces Immunomodulatory Alpha Neutrophils (IMANs), enhanced neutrophils designed to overcome treatment resistance in solid tumors. IMANs can identify and kill solid tumors irrespective of antigen, both directly and indirectly by recruiting the patient's own cancer-killing immune cells.
LIfT will collaborate with ScaleReady to establish a fully closed and semi-automated G-Rex manufacturing process suitable for late-stage clinical trials and beyond. The G-Rex Grant Program is a $20M initiative to advance cell and gene-modified cell therapy development and manufacturing.